Children with high-risk neuroblastoma (NB) have a poor clinical outcome. The purpose of the present study was to evaluate different strategies for immunotherapy of high-risk NB based on vaccination with antigen-loaded dendritic cells (DCs). DCs are professional antigen-presenting cells with the ability to induce antitumor T-cell responses. We have compared DCs either loaded with apoptotic tumor cells or transfected with mRNA from the NB cell line HTB11 SK-N-SH, for their capacity to induce T-cell responses in vitro. Monocyte-derived DCs from healthy donors were loaded with tumor-derived antigens in the form of apoptotic cells or mRNA, matured and used to prime autologous T cells in vitro. After 1 week, T-cell responses against antigen-loaded DCs were measured by ELISPOT assay. DCs loaded with apoptotic NB cells or transfected with NB-cell mRNA were both able to efficiently activate autologous T cells. Both T cells of the CD8 þ and CD4 þ subset were activated. T cells activated by NB mRNA transfected DCs extensively crossreacted with DCs loaded with apoptotic NB cells and vice versa. The results indicate that loading of DCs with apoptotic NB cells or transfection with tumor mRNA represent promising strategies for development of individualized cancer vaccines/cancer gene therapy in treatment of NB.
N euroblastoma (NB) is a tumor arising from sympathetic nervous system, and represents the most common extra cranial solid tumor of infants and young children. NB is remarkable for its broad spectrum of clinical behavior, 1 and prognosis depends on dissemination through the body. Children with stages 1 and 2 can be cured with surgery alone. Most infants with disseminated disease have favorable outcomes following treatment with chemotherapy and surgery. 2 However, the majority of children older then 1 year of age with advanced-stage NB die from progressive disease despite intensive multimodality therapy. 3 In addition, many of the successful therapies are associated with toxicity leading to long-term morbidity and an increasing second malignancy rate. Thus, new therapies that offer less toxicity to treat NB are being explored. 4 As an alternative, immunotherapy is moving to become a promising option in cancer therapy. Tumor vaccines aim to induce T-cell responses against tumor specific antigens. Using a patients' own tumor cells as a source of antigen, autologous DCs presenting cancer antigens may prove to be an ideal vaccine against NB.
In the case of high-risk NB resistant to conventional treatment DC-based immunotherapy might offer a novel therapeutic option. The activation of a T-cell response consisting of tumor specific T-helper cells (Th) and cytotoxic T lymphocytes (CTLs) requires presentation of the antigen in the context of major histocompatibility complex (MHC) molecules on the surface of antigenpresenting cells. 5 Vaccination with tumor antigen-loaded DCs have been shown to induce both Th and CTL responses, and tumor regression in some patients. [6] [7] [8] An important issue in optimizing DC vaccines is the choice of tumor antigen for loading of DCs. Many clinical trials in patients with melanoma have demonstrated that vaccination against a single antigen can induce tumor specific CTLs. 9 However, for many tumors, no antigenic epitopes are known. 10 Effective cross-priming with antigens from tumor cells has been demonstrated with apoptotic tumor cells. [11] [12] [13] A phase-I trial using tumor-lysate-pulsed DCs in therapy of several different pediatric solid tumors has been reported, 6 in which one case involved an NB patient.
Furthermore, loading of DCs with tumor RNA has also been shown to be an attractive alternative in the development of DC-based tumor vaccines.
14 Due to difficulties of setting up an autologous test system based on clinical material from children with NB, we have chosen an experimental system based on an established NB cell line, HTB11-SK-N-SH, and monocyte derived DC from blood donor buffy-coats. In the present study we have thus compared DCs either loaded with apoptotic NB cells or transfected with mRNA isolated from NB cells, for their ability to generate T-cell responses against antigens derived from NB cells. In this study we describe important in vitro findings that will aid the development of autologous tumor vaccines/immunogene therapy for NB patients. We show that both strategies can be successfully employed to induce both CD4 þ and CD8 þ T-cell responses against antigens derived from NB tumor cells.
Materials and methods

Cytokines and chemicals
GM-CSF was purchased from Novartis (Basel, Switzerland), IL-4, TNFa, IL1b and IL-6 from CellGenix (Freiburg, Germany), Prostaglandin E2 (PgE 2 ), IL-7, IL-2 and IL-12 from R&D Systems (Minneapolis, USA). Staurosporine was obtained from (Sigma Aldrich).
Preparation of DCs and T cells
PBMC from healthy donors (obtained from Buskerud Hospital, Drammen, Norway) were obtained by density gradient centrifugation (Lymphoprep, Nycomed, Norway). Monocyte-derived DCs were generated under serum-free conditions from the adherent fraction of PBMCs cultured in six-well plates at a density of 4 Â 10 6 cells/ml for 1.5 hours at 371C in 3 ml CellGro DC medium (CellGenix, Freiburg, Germany). Nonadherent cells were collected and frozen for later use as responder cells. The adherent cells were cultured in 3 ml CellGro DC medium, supplemented with 800 U/ml GM-CSF and 10 ng/ml IL-4 every second day, until day 5 when maturation of DCs was induced by the addition of maturation cocktail (10 ng/ml TNF-a, 10 ng/ml IL-1b, 1,000 U/ml IL-6 and 1 mg/ml PgE 2 ) for 24 hours. Characterization of DC phenotypes was carried out by staining with fluorochrome-labelled antibodies against the Lin1 panel (CD3, CD14, CD19, CD16, CD20, CD56), HLA-DR, CD1a, CD25, CD80, CD83 and CD86 (Becton Dickinson, San Jose, CA), and analyzed by FACSCalibur flow cytometery (Becton Dickinson).
Phagocytosis of apoptotic cells
NB cell line HTB11 SK-N-SH were stained with the green fluorescent dye PKH-67 (Sigma Aldrich), as described in the kit manual and exposed to 1 mM staurosporine for 12 hours to induce apoptosis. Apoptotic cell death was assessed by using Annexin V-FITC as described by the manufacturer (Boehringer Manheim, Manheim, Germany). For evaluation of phagocytosis, apoptotic NB cells were incubated with immature DCs in ratio of 3:1. After 6 hours, immature DCs were labeled with a red fluorescent antibody (mAb CD1a-PE). Phagocytosis was measured quantitatively by flow cytometry, and intracellular uptake of apoptotic cells was visualized by confocal laser microscopy (Leica TCS SP, HeNe and Ar laser, 63X/ 1.20 W CORR CS, HCX PL APO).
Preparation of NB-cell mRNA and transfection of DCs
The NB cell line HTB11 SK-N-SH, obtained from American Type Culture Collection (ATCC), was used as a source of tumor material. Total RNA was isolated from 20-25 Â 10 6 cells using Trizol Reagent as described by the manufacturer (Invitrogen, Basel, Switzerland). Poly(A) þ mRNA was isolated from total RNA using the GenoPrep Direct mRNA kit (GenoVision, Oslo, Norway). The mRNA was used fresh or stored at À801C until use. Transfection of DCs with mRNA was performed as described previously, 10 but with minor modifications. Briefly, immature DCs were washed once, resuspended in RPMI-1640 (BIO-Whittaker, Walkersville, MD) and placed on ice. A measure of 200 ml (approx. 2 Â 10 6 ) cells were mixed with 40 ml mRNA, transferred to a 2-mm-gap cuvette and pulsed with a BTX ECM-830 square-wave electroporator (Genetronics Inc., San Diego, CA) using instrument settings 800 V and 200 ms. Transfected cells were incubated on ice for 30 s followed by addition 2.0 ml cold CellGro DC medium supplemented with 10 ng/ml IL-4, 800 U/ml GM-CSF and maturation cocktail (see above), and transferred to standard culturing conditions. Transfection with EGFP-pCIpA 102 mRNA encoding enhanced green fluorescence protein 10 was used to verify transfection efficiency.
Induction of primary CTL responses
Mature DCs (0.3 Â 10 6 ) expressing NB-cell mRNA or loaded with apoptotic NB cells were used to prime autologous nonadherent PBMCs (3 Â 10 6 ) in 1.0 ml CellGro DC medium without serum and cultured for 7 days at 371C in a humidified incubator with 5% CO 2 in air. Cultures were set up in duplicate.
ELISPOT assay
The duplicate cultures were pooled and tested in an enzyme-linked immunosorbent spot (ELISPOT) assay 15 by restimulation with thawed antigen-loaded DC on day 7 using 0.2 Â 10 5 ; 0.5 Â 10 5 , 1 Â 10 5 and 2 Â 10 5 responding cells and 0.5 Â 10 4 DCs per well. Mock transfected DCs were used as control. The assay was carried out in duplicate. Spots were counted manually, and the frequency of reactive T cells was calculated. In some experiments, the responding T-cell population was divided into CD4 þ and CD8 þ T cells after in vitro priming by negative selection using Dynabeads (Dynal, Oslo, Norway). These fractions were then tested individually in the ELISPOT assay for IFNg secreting T cells.
Monoclonal antibody against human interferon-g (IFN-g)
Evaluation of autologous dendritic cells transfected with mRNA S Jarnjak-Jankovic et al (Mabtech 1-D1 K, 1 mg/ml) was diluted with PBS to a final concentration of 2 mg/ml. Each well in a 96-well plate (Millipore-MAIP N45) were coated with antibody by adding 75 ml of the stock solution and incubated overnight at 41C. The following day, the plate was stored at room temperature for 1 hours and to remove excess antibody each well was washed six times with 200 ml PBS in each well. To block unspecific binding, the plate was incubated for 1-2 hours at 371C with 100 ml per well of RPMI-1640 plus 1% human albumin. The responder cells were harvested, washed, enumerated and transferred to the precoated wells in different cell concentrations. Thawed and washed transfected DCs from the same donor were counted and added to the precoated wells containing responder cells. As control, mock-transfected DC, responder cells alone or medium alone were used. After overnight incubation at 371C in 5% CO 2 in a humidified incubator, the plates were washed six times with PBS. To each well, 75 ml of a stock solution of 0.75 mg/ml of biotinylated antibody against human IFN-g (Mabtech, 7-B6-1-biotin, 1 mg/ml) was added and the plate was incubated for 2 hours at room temperature. Following six washings, the plate was incubated for 1 hours with 75 ml per well of streptavidin-ALP (Mabtech, 3310-8). To remove excess antibodies, the cells were again washed six times. Then, after adding 75 ml of substrate BCIP/NBT (Sigma B911) to each well, the plate was incubated for 4-5 minutes. When spots appeared, water was added to stop the reaction. The number of spots per well was counted under a stereomicroscope, and the frequency of reactive T cells was calculated.
Results
Uptake of apoptotic NB cells by immature human DCs
Based on the observations that immature DCs are the cells responsible for capturing antigens, we first investigated if immature DCs also efficiently phagocytozed apoptotic NB cells. Immature DCs were prepared from PBMC in the presence of IL-4 and GM-CSF. The DCs were examined for surface expression of Lin1 panel, CD1a, CD25, HLA-DR, CD80, CD83 and CD86 by immuno staining and flow cytometry. As shown in Figure 1a , the DCs displayed the characteristic immature phenotype with high expression of CD1a and HLA-DR, and low expression of CD25, CD80, CD83 and CD86. For induction of apoptosis, NB cells were treated by staurosporine. In an independent series of experiments, optimal early apoptosis was observed after 12 hours (data not shown), and used as early apoptotic cells in all experiments. To document apoptosis after 12 hours exposure to staurosporine, the cells were stained with Evaluation of autologous dendritic cells transfected with mRNA S Jarnjak-Jankovic et al
Annexin-V and examined by flow cytometry. All the cells were observed to be Annexin-V positive (Fig 2a) . Furthermore, confocal microscopy revealed that apoptotic NB cells showed typical morphological changes characteristic of apoptotic cells (Fig 2b) .
To study uptake of apoptotic NB cells by immature DCs, NB cells were stained with the green fluorescent dye PKH-67 before induction of apoptosis. Immature DCs were stained with the red fluorescent dye PKH-26. The apoptotic NB cells were then coincubated with immature DCs for various periods of time to determine the optimal conditions for internalization of apoptotic NB cells. We observed that immature DCs ingested apoptotic NB cells within 6 hours of coincubation. Apoptotic NB cells (green stained) were detected during phagocytosis in phagocytic cups and inside the immature DCs (red stained) by confocal microscopy (Fig 3b) . Using flow cytometry, highly efficient uptake of apoptotic NB cells was confirmed, since virtually all CD1a positive cells also showed green PKH-67 staining (Fig 3a) . The DCs were then matured in the presence of proinflammatory cytokines for 24 hours. This led to upregulation of CD83, CD80 and CD86, which is characteristic of a mature DC phenotype (Fig 4) .
DCs transfected with mRNA from NB cells
Transfection of cells with tumor-derived mRNA is an alternative method for loading of DCs with tumor antigens. mRNA from the NB cell line HTB11 SK-N-SH was isolated. The method of electroporation to transfer tumor mRNA into DCs has been described previously.
10 Following this protocol we tested several parameters and observed that optimal conditions were 800 V and 200 ms in the 2 mm cuvette (data not shown). Under these conditions a mean cell viability of 70.4% after electroporation was observed. The efficacy of mRNA transfection was confirmed by flow cytometry (Fig 5a) and fluorescence microscopy (Fig 5b) . Furthermore, the phenotype of mature DCs after mRNA transfection was confirmed by flow cytometry (Fig 6) . We also observed that after maturation, mRNA transfected DCs expressed more CD25 as compared with mature DCs that had been loaded with apoptotic NB cells (Fig 4) .
ELISPOT analysis for IFN-g-releasing, NB specific T cells
For T-cell responses against cancer vaccines representing a heterogeneous mixture of (unknown) antigens presented by many different HLA molecules, the ELISPOT assay is the method of choice. This assay measures in a quantitative way the number of reactive T cells in preand postvaccination samples, and thus directly relates the effect of vaccination to in vivo expansion of reactive T cells. The ELISPOT assay was accordingly used to detect specific T-cell responses also in these preclinical Evaluation of autologous dendritic cells transfected with mRNA S Jarnjak-Jankovic et al experiments. As shown in Figure 7 , T cells primed for 1 week with thawed antigen-loaded DCs demonstrated a specific T-cell response against antigen-loaded DCs as compared to control DCs (mock transfected). No significant difference between the two modes of antigen loading was observed. Similar results were obtained in three additional experiments using cells from three other normal donors. The frequencies of specific spots in all experiments are summarized in Table 1 .
To address which T-cell subpopulation was responsible for the IFNg spot forming cells, we separated the responding T-cell population into a CD4 þ and a CD8 þ T-cell fraction, using negative selection with Dynabeads coated with CD8 and CD4 antibodies, respectively. The results shown in Figure 8 demonstrate that both a CD4 and a CD8 response was obtained in all three donors investigated. Both methods of antigen loading resulted in combined CD4 and CD8 responses. Although the frequency of specific T cells varied between donors, the results of these experiments indicate that mRNA loading is more efficient than apoptotic cells in priming of a T-cell response.
Theoretically, the two modes of antigen loading of DCs could result in different peptide repertoires being expressed by the DCs and hence give rise to nonoverlapping T-cell responses. To address this, we primed T cells with the two types of antigen loading DCs and tested the responding T cells in a crossover experiment using both types of DCs as APC's for both types of primed T cells in the ELISPOT assay. To also investigate the extent of crossreactivity within the different T-cell subpopulations, we separated the responding T cells into a CD4 þ and a CD8 þ fraction as described above. The results are depicted in Figure 9 and clearly demonstrate for all three donors that T cells primed one way or the other equally well-recognize DCs loaded with apoptotic cells or transfected with mRNA. This result indicates that a highly overlapping T-cell repertoire is activated. Dissection of the responding T cells into CD4 þ and CD8 þ T cells also indicated that no major differences in the involvement of T cells from the two subsets could be detected following antigen loading by the two different methods.
Discussion
New strategies are required for the development of therapeutic alternatives for high-risk NB. Further development of biologically based treatment may give rise to effective therapy for patients suffering from this disease. There are currently a large number of early stage clinical trials evaluating DC-based vaccines in the therapy of Evaluation of autologous dendritic cells transfected with mRNA S Jarnjak-Jankovic et al cancer in adult patients. 5, 6, 14, 16 Induction of CTLs with antitumor activity has been demonstrated after loading of DCs with apoptotic tumor cells, [11] [12] [13] but to Evaluation of autologous dendritic cells transfected with mRNA S Jarnjak-Jankovic et al our knowledge, no comparison has been made between loading of DCs with mRNA or apoptotic cells. In this study, we investigated the ability of monocyte-derived DCs loaded with different antigen preparations to induce a T-cell response against antigens present in a NB cell line, in an ex vivo model. The antigen preparations consisted of mRNA isolated from NB cells or apoptotic NB cells. Our results clearly demonstrate that immature DCs engulf apoptotic NB cells. Further, efficient transfection of the same DC preparations with mRNA encoding EGFP could be demonstrated, indicating that also antigens encoded by mRNA prepared from the NB cell line would be expressed following transfection. In order to compare the efficacy of antigen loading by the two methods, we decided to use a readout system in vitro that represents as closely as possible the actual immune stimulation occurring in a vaccinated patient. Accordingly, we matured the antigen-loaded DCs using a conventional maturation cocktail, which can also be used for GMP production of an actual vaccine. Our findings indicate that the different methods of antigen loading did not result in major differences in the phenotype of the mature DCs, as mature DC from the same donor expressed the expected phenotype irrespective of antigen loading. One exception was the expression of CD25, which was lower in transfected cells. CD25 has been reported to be expressed on mature DCs, 17 and may be involved in the induction of IFN-g production by DCs in mice. In general, the expression of CD25 turned out to be quite variable between different donors (7-65%). The biological significance of CD25 expression in man is so far not known.
Similar results were obtained in the functional assays, where only minor differences in the capacity to elicit specific T-cell responses were observed when DCs loaded by the two methods were compared. In these experiments we investigated the T-cell responses after priming for 7 days in vitro. In a series of initial experiments, we observed very high backgrounds when recombinant cytokines (IL-2, IL-7 and IL-12) were added to the cultures. The background was persistent and obscured the specific responses, even after 3-5 rounds of stimulation (data not shown). The present set of experiments was therefore performed in the absence of exogenously added cytokines. These experimental conditions may have biased our results, by leading to preferential proliferation of specific T cells capable of autocrine production of growth factors. Nonetheless, we can conclude that both Evaluation of autologous dendritic cells transfected with mRNA S Jarnjak-Jankovic et al methods of antigen loading are capable of stimulating the activation of such T cells, and that the frequency of specific T cells activated following the two antigenloading procedures was similar. The mean frequency of specific T cells under these experimental conditions was approximately 2/10,000, based on the ELISPOT assays ( Table 1) .
The two different loading procedures introduce antigens into the DC by fundamentally different pathways that theoretically could lead to expression of nonoverlapping sets of peptides. Uptake of apoptotic tumor cells via phagocytosis results in presentation of antigenic proteins via the endocytic pathway, and is mainly expected to result in the generation of HLA-class II restricted Thelper cells. mRNA electroporation, on the other hand, will result in introduction of tumor mRNA into the cytoplasm of the DCs. Subsequently, expression of the encoded proteins will occur in the endoplasmatisc reticulum and other cellular compartments, finally resulting in processing via the endogenous pathway. This will mainly result in the generation of CTL epitopes by proteosomal processing. Based on this it could be expected that the two different methods of antigen loading not only would result in the generation of T cells specific for different antigens but also in T-cell responses involving different types of T cells. To test if this was the case, we performed crossover experiments, testing the ability of T cells primed with the two different types of DC to recognize DCs loaded by the two different procedures. Our results unequivocally demonstrated that the responding T-cell populations overlapped extensively in their specificity and that no pronounced difference in the involvement of the two T-cell subpopulations was observed. Such an overlap in specificity strongly indicates that the two pathways are ''leaky''. It is known that the endocytic pathway is leaky and also gives rise to the generation of CTL epitopes through translocation of antigens into the cytosol and subsequent delivery of CTL epitopes into endosomes that have fused with ER. 18 Also, tumor-mRNA-transfected DCs used as vaccines in cancer patients elicit strong helper T-cell responses (Mu et al submitted), indicating that tumor antigens introduced into DCs via mRNA transfection also may be processed via an endosomal pathway.
In the present study, we took advantage of the broad repertoire of antigenic differences that exist between the established cancer line used and the allogeneic T cells and DCs used in the experiments. This strategy allowed us to compare the two methods of antigen loading, and provided us with a large number of unknown antigens with the potential to be processed both for HLA-class I and class II presentation. In our opinion, none of these antigens need to be tumor antigens to prove the validity of the concept. It would of course be of great interest to get detailed knowledge of the antigens recognized following the types of ''shotgun'' vaccinations investigated here. Determination of the specificity of the responding T cells is however clearly beyond the scope of this article, since it would require elaborate techniques such as cloning of the responding T cells and cotransfection of the restricting T cells and cDNA libraries into target cells.
The aim of this study was to establish procedures whereby potentially broadly antigenic tumor cells could be used as a source of antigens for a DC-based vaccine. Recently, tumor mRNA has come up as a particularly attractive source for tumor antigens. Thus, while protein antigens from tumor lysate are rapidly proteolyzed following endocytosis by antigen-presenting cells, model experiments using mRNA encoding a fluorescent protein, EGFP, has shown that protein is still being produced 24 hours after transfection of DCs, with peak expression after 48 hours. 10 Moreover, using this method, CTL's against a general tumor antigen, the hTERT subunit of telomerase, could efficiently be primed by hTERTmRNA transfected human DCs. 10 The presence of a source of antigen that continuously feeds the antigen processing machinery is considered to be of great importance in vaccination. In vaccine preparations using DCs, mRNA is thus preferable to a protein lysate. In model systems in vitro and in vivo, it has been shown that vaccination with tumor-RNA-transfected DCs can be Evaluation of autologous dendritic cells transfected with mRNA S Jarnjak-Jankovic et al remarkably effective in stimulating CTL immunity. 19 Recently, Heiser et al, 20 demonstrated that autologous human DCs transfected with RNA amplified from microdissected tumor cells are capable of stimulating CTL against a broad set of unidentified and critical prostate-specific antigens in vitro. Thus, both human and animal studies have demonstrated that DCs can efficiently mediate induction of antitumor immunity. 21 The results of these preclinical experiments have formed the basis for the development of a Phase I/II protocol, which will test DC vaccines in the treatment of high-risk NB in the clinic. The primary objective of this protocol is safety aspects and the secondary objective an evaluation of the immunogenicity of DCs loaded with autologous NB mRNA and establishment of a correlation between immune responses and clinical efficacy.
